GRPR and cancer: This finding in combination with the lack of physiological GRPR expression in healthy tissues (with the exception of the GRPR-rich pancreas and gastrointestinal tract [14]) has provided the rationale for using properly designed BBN-like peptide carriers of radionuclides in malignant lesions for cancer theranostics [2,15,16].